TrialInternational journal of clinical practice2017

A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment.

Antonio Chacra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.